For a patient with confirmed endometriosis who has failed NSAIDs, hormonal therapy, GnRH analogues, or surgery, is cannabis an appropriate treatment for pain and what dosing regimen and safety considerations should be used?

Cannabis for Endometriosis-Associated Pain

Cannabis-based medicinal products (CBMPs) should be considered as a treatment option for endometriosis-associated pain in patients who have failed conventional therapies, though this recommendation is based on observational data rather than high-quality randomized controlled trials.

Current Evidence Base

The evidence for cannabis in endometriosis consists entirely of observational studies and patient surveys—no randomized controlled trials exist 1, 2. The most recent longitudinal data from the UK Medical Cannabis Registry (2026) showed improvements in pain scores and quality of life measures at 18 months in 63 patients with endometriosis-associated chronic pain 3. This represents the highest quality prospective data available, though causality cannot be definitively established due to the observational design.

Clinical Efficacy

Pain reduction appears substantial based on patient-reported outcomes:

• The UK registry study demonstrated statistically significant improvements in all pain-specific measures from baseline to 18 months (p < 0.050), with minimal clinically significant differences observed in 11-37% of patients and moderately important improvements in 5-22% 3
• Cross-sectional surveys consistently report that 57.3-95.5% of endometriosis patients use cannabis primarily for pain management 1
• Substantial medication substitution effects were documented: >50% reduction in nonopioid analgesics (63.1%), opioid analgesics (66.1%), and antineuropathics (61.7%) 4

Dosing and Administration

No standardized dosing protocols exist for endometriosis. The available evidence shows:

• Route of administration: Inhalation (51.6-80.3%) and oral ingestion (25-76.9%) are most commonly used 1
• Start low and titrate slowly: Given the lack of formal dosing studies, begin with the lowest available dose and increase gradually based on symptom response
• Medical supervision is essential: Monitor for efficacy, adverse effects, and potential drug interactions

Critical caveat: The "drug label" evidence provided 5 pertains to theophylline, not cannabis, and should be disregarded as irrelevant to this clinical question.

Safety Profile and Adverse Events

Adverse events are common but generally mild:

• Reported by 10.2-52.0% of patients in surveys 1
• Most common: euphoria ("feeling high") and dry mouth 1
• Serious concerns include potential for cannabis use disorder, psychosis, and mood disturbances with long-term use 2
• 62 adverse events were documented in the UK registry cohort, reported by 25.4% of participants 3

Critical Clinical Considerations

Legal and disclosure issues create significant barriers:

• 72% of Australian and 88.2% of New Zealand respondents use cannabis illicitly despite legal medical pathways existing 4
• 18.8-30% of patients do not disclose cannabis use to physicians due to fear of legal repercussions, stigma, or negative reactions 4, 6
• This lack of medical oversight is dangerous because it prevents monitoring for drug interactions, particularly when patients reduce or stop other medications without supervision 4

Drug interactions and medication tapering:

When patients self-report reducing pharmaceutical medications due to cannabis use, you must:

• Explicitly discuss all medications they are taking or have stopped
• Monitor for withdrawal effects from abruptly discontinued medications (especially opioids, benzodiazepines, antidepressants)
• Assess for potential interactions between cannabis and remaining medications
• Document cannabis use in the medical record

Practical Implementation Algorithm

For patients requesting cannabis after failing conventional therapies:

1. Confirm treatment failures: Document inadequate response to NSAIDs, hormonal therapies, GnRH analogues, and surgical options
2. Screen for contraindications: Personal or family history of psychosis, substance use disorder, pregnancy/breastfeeding plans, occupations requiring drug testing
3. Discuss legal access pathways: Prescribe through legitimate medical cannabis programs rather than allowing illicit use
4. Set realistic expectations: Explain the observational nature of evidence and that individual response varies
5. Start with CBD-predominant products: These may have fewer psychoactive effects while maintaining anti-inflammatory and analgesic properties
6. Schedule close follow-up: Assess at 1,3, and 6 months for efficacy, adverse effects, and changes in other medication use
7. Monitor for dependence: Regular assessment for problematic use patterns

Evidence Limitations and Guideline Gaps

The ACR guideline on endometriosis 7 focuses exclusively on imaging and does not address cannabis treatment. No major gynecology society guidelines currently recommend cannabis for endometriosis due to insufficient high-quality evidence 2.

The UK guidance reviewed in 2022 states that cannabis-based products can only be prescribed when there is clear published evidence of benefit and all other treatment options have been exhausted 2. The 2026 UK registry data 3 provides the most compelling evidence to date, though it remains observational.

Bottom Line

Given the substantial patient-reported benefits, low satisfaction with conventional treatments, and generally tolerable safety profile, a trial of medical cannabis is reasonable in refractory endometriosis pain—but only under medical supervision through legal channels. The alternative is patients using illicit cannabis without medical oversight, which poses greater risks. Document the discussion, obtain informed consent acknowledging the limited evidence base, and monitor closely for both benefits and harms 8, 3.